180 related articles for article (PubMed ID: 22689946)
1. Presensitizing with a Toll-like receptor 3 ligand impairs CD8 T-cell effector differentiation and IL-33 responsiveness.
Ngoi SM; St Rose MC; Menoret AM; Smith DE; Tovey MG; Adler AJ; Vella AT
Proc Natl Acad Sci U S A; 2012 Jun; 109(26):10486-91. PubMed ID: 22689946
[TBL] [Abstract][Full Text] [Related]
2. Targeting poly(I:C) to the TLR3-independent pathway boosts effector CD8 T cell differentiation through IFN-alpha/beta.
Ngoi SM; Tovey MG; Vella AT
J Immunol; 2008 Dec; 181(11):7670-80. PubMed ID: 19017955
[TBL] [Abstract][Full Text] [Related]
3. Immunoadjuvant effects of polyadenylic:polyuridylic acids through TLR3 and TLR7.
Sugiyama T; Hoshino K; Saito M; Yano T; Sasaki I; Yamazaki C; Akira S; Kaisho T
Int Immunol; 2008 Jan; 20(1):1-9. PubMed ID: 17981792
[TBL] [Abstract][Full Text] [Related]
4. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu.
Salem ML; El-Naggar SA; Kadima A; Gillanders WE; Cole DJ
Vaccine; 2006 Jun; 24(24):5119-32. PubMed ID: 16704888
[TBL] [Abstract][Full Text] [Related]
5. TLR3 ligand polyinosinic:polycytidylic acid induces IL-17A and IL-21 synthesis in human Th cells.
Holm CK; Petersen CC; Hvid M; Petersen L; Paludan SR; Deleuran B; Hokland M
J Immunol; 2009 Oct; 183(7):4422-31. PubMed ID: 19748983
[TBL] [Abstract][Full Text] [Related]
6. IL-21 promotes differentiation of naive CD8 T cells to a unique effector phenotype.
Casey KA; Mescher MF
J Immunol; 2007 Jun; 178(12):7640-8. PubMed ID: 17548600
[TBL] [Abstract][Full Text] [Related]
7. Cutting edge: polyinosinic:polycytidylic acid boosts the generation of memory CD8 T cells through melanoma differentiation-associated protein 5 expressed in stromal cells.
Wang Y; Cella M; Gilfillan S; Colonna M
J Immunol; 2010 Mar; 184(6):2751-5. PubMed ID: 20164430
[TBL] [Abstract][Full Text] [Related]
8. IL-21 sustains CD28 expression on IL-15-activated human naive CD8+ T cells.
Alves NL; Arosa FA; van Lier RA
J Immunol; 2005 Jul; 175(2):755-62. PubMed ID: 16002671
[TBL] [Abstract][Full Text] [Related]
9. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity.
Salem ML; Kadima AN; Cole DJ; Gillanders WE
J Immunother; 2005; 28(3):220-8. PubMed ID: 15838378
[TBL] [Abstract][Full Text] [Related]
10. The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naïve recipient mice.
Salem ML; Diaz-Montero CM; El-Naggar SA; Chen Y; Moussa O; Cole DJ
Vaccine; 2009 Jan; 27(4):549-57. PubMed ID: 19027047
[TBL] [Abstract][Full Text] [Related]
11. Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method.
Nordly P; Rose F; Christensen D; Nielsen HM; Andersen P; Agger EM; Foged C
J Control Release; 2011 Mar; 150(3):307-17. PubMed ID: 21111765
[TBL] [Abstract][Full Text] [Related]
12. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells.
Yang Q; Li G; Zhu Y; Liu L; Chen E; Turnquist H; Zhang X; Finn OJ; Chen X; Lu B
Eur J Immunol; 2011 Nov; 41(11):3351-60. PubMed ID: 21887788
[TBL] [Abstract][Full Text] [Related]
13. Synergy of TLR3 and 7 ligands significantly enhances function of DCs to present inactivated PRRSV antigen through TRIF/MyD88-NF-κB signaling pathway.
Hu Y; Cong X; Chen L; Qi J; Wu X; Zhou M; Yoo D; Li F; Sun W; Wu J; Zhao X; Chen Z; Yu J; Du Y; Wang J
Sci Rep; 2016 Apr; 6():23977. PubMed ID: 27046485
[TBL] [Abstract][Full Text] [Related]
14. Viral dsRNA-activated human dendritic cells produce IL-27, which selectively promotes cytotoxicity in naive CD8+ T cells.
de Groot R; van Beelen AJ; Bakdash G; Taanman-Kueter EW; de Jong EC; Kapsenberg ML
J Leukoc Biol; 2012 Sep; 92(3):605-10. PubMed ID: 22701040
[TBL] [Abstract][Full Text] [Related]
15. A Highly Active Form of XCL1/Lymphotactin Functions as an Effective Adjuvant to Recruit Cross-Presenting Dendritic Cells for Induction of Effector and Memory CD8
Matsuo K; Kitahata K; Kawabata F; Kamei M; Hara Y; Takamura S; Oiso N; Kawada A; Yoshie O; Nakayama T
Front Immunol; 2018; 9():2775. PubMed ID: 30542351
[TBL] [Abstract][Full Text] [Related]
16. Common gamma chain cytokines: dissidence in the details.
Alves NL; Arosa FA; van Lier RA
Immunol Lett; 2007 Feb; 108(2):113-20. PubMed ID: 17194484
[TBL] [Abstract][Full Text] [Related]
17. Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8(+) T cells during vaccine immunotherapy.
Takeda Y; Azuma M; Matsumoto M; Seya T
J Exp Clin Cancer Res; 2016 Sep; 35(1):143. PubMed ID: 27619885
[TBL] [Abstract][Full Text] [Related]
18. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
[TBL] [Abstract][Full Text] [Related]
19. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.
Hinrichs CS; Spolski R; Paulos CM; Gattinoni L; Kerstann KW; Palmer DC; Klebanoff CA; Rosenberg SA; Leonard WJ; Restifo NP
Blood; 2008 Jun; 111(11):5326-33. PubMed ID: 18276844
[TBL] [Abstract][Full Text] [Related]
20. IL-10 distinguishes a unique population of activated, effector-like CD8
Rood JE; Canna SW; Weaver LK; Tobias JW; Behrens EM
J Leukoc Biol; 2017 Apr; 101(4):1037-1044. PubMed ID: 28034913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
